5171 - 5180 of 8818 Results
Title
Year
-
OPENTitle: SORL1 mutation in a Greek family with Parkinson's disease and dementiaJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 8Issue #: 10Start Page: 1961End Page: 1969Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.51433Best OA location URL: https://doi.org/10.1002/acn3.51433Citation Count: 8
-
OPENTitle: The Michael J. Fox Foundation's quest for a cure for Parkinson's disease: an interview with Nicole PolinskiJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 16Issue #: 12Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.050605Best OA location URL: https://journals.biologists.com/dmm/article-pdf/16/12/dmm050605/3311458/dmm050605.pdfCitation Count: 0
-
OPENTitle: An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 2Start Page: 623End Page: 629Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-191786Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd191786?id=journal-of-parkinsons-disease%2Fjpd191786Citation Count: 43
-
OPENTitle: Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 4Start Page: 1663End Page: 1675Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212672Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212672?id=journal-of-parkinsons-disease%2Fjpd212672Citation Count: 30
- Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?2023OPENTitle: Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?Journal Name: Current NeuropharmacologyPublisher: Bentham Science Publishers Ltd.Vol: 22Issue #: 10Start Page: 1583End Page: 1605Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.2174/1570159x21666230801140648Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/11284713Citation Count: 1
-
OPENTitle: Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: A comparative study with tranylcypromineJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 128Issue #:Start Page: 107158End Page: 107158Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2024.107158Best OA location URL: https://www.prd-journal.com/article/S1353-8020(24)01170-2/pdfCitation Count: 2
-
OPENTitle: Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemicJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 15Issue #: 12Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.049755Best OA location URL: https://doi.org/10.1242/dmm.049755Citation Count: 0
-
OPENTitle: Age at onset and Parkinson disease phenotypeJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 86Issue #: 15Start Page: 1400End Page: 1407Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000002461Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/4831034Citation Count: 328
-
OPENTitle: Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controlsJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 89Issue #: 19Start Page: 1959End Page: 1969Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1212/wnl.0000000000004609Best OA location URL: https://n.neurology.org/content/neurology/89/19/1959.full.pdfCitation Count: 145
-
RESTRICTEDTitle: Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease (4418)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.4418Citation Count: 0